210 related articles for article (PubMed ID: 36581954)
1. FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma.
Zhang G; Guo C; Wang Y; Zhang X; Liu S; Qu W; Chen C; Yan L; Yang Z; Zhang Z; Jiang X; Chen X; Liu H; Lai Q; Wei X; Lu Y; Zhao S; Deng H; Wang Y; Yu L; Yu H; Wu Y; Su Z; Chen P; Ren Z; Yu M; Qu F; Luo Y; Gou L; Li Q; Huang Y; Ma F; Yang J
J Hematol Oncol; 2022 Dec; 15(1):177. PubMed ID: 36581954
[TBL] [Abstract][Full Text] [Related]
2. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Kassem S; Diallo BK; El-Murr N; Carrié N; Tang A; Fournier A; Bonnevaux H; Nicolazzi C; Cuisinier M; Arnould I; Sidhu SS; Corre J; Avet-Loiseau H; Teillaud JL; van de Velde H; Wiederschain D; Chiron M; Martinet L; Virone-Oddos A
Blood; 2022 Feb; 139(8):1160-1176. PubMed ID: 35201323
[TBL] [Abstract][Full Text] [Related]
3. Anti CD38 monoclonal antibodies for multiple myeloma treatment.
Gozzetti A; Ciofini S; Simoncelli M; Santoni A; Pacelli P; Raspadori D; Bocchia M
Hum Vaccin Immunother; 2022 Nov; 18(5):2052658. PubMed ID: 35404740
[TBL] [Abstract][Full Text] [Related]
4. Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity.
Liu W; Yu J; Sun K; Song Q; Li Y; He Y; Wang Y; Xu G; Wang C; Chen B
Front Immunol; 2024; 15():1410457. PubMed ID: 38765013
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping.
Chami B; Okuda M; Moayeri M; Pirenne F; Hidaka Y; Nambiar A; Song Z; Bedel O; Zhang B; Hopke J; Deng G; Zhu C; Macé S; Chiron M; Adrian F; Fukao T; Basile FG; Martin T
Transfusion; 2022 Nov; 62(11):2334-2348. PubMed ID: 36239134
[TBL] [Abstract][Full Text] [Related]
6. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
van de Donk NWCJ; Usmani SZ
Front Immunol; 2018; 9():2134. PubMed ID: 30294326
[TBL] [Abstract][Full Text] [Related]
7. CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells.
Wang H; Koob T; Fromm JR; Gopal A; Carter D; Lieber A
Cancer Biol Ther; 2024 Dec; 25(1):2314322. PubMed ID: 38361357
[TBL] [Abstract][Full Text] [Related]
8. CD38 targeted treatment for multiple myeloma.
Jelínek T; Mihályová J; Hájek R
Vnitr Lek; 2018; 64(10):939-948. PubMed ID: 30590941
[TBL] [Abstract][Full Text] [Related]
9. Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity.
Hiemstra IH; Santegoets KCM; Janmaat ML; De Goeij BECG; Ten Hagen W; van Dooremalen S; Boross P; van den Brakel J; Bosgra S; Andringa G; van Kessel-Welmers B; Verzijl D; Hibbert RG; Frerichs KA; Mutis T; van de Donk NWCJ; Ahmadi T; Satijn D; Sasser AK; Breij ECW
EBioMedicine; 2023 Jul; 93():104663. PubMed ID: 37379657
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma.
Panaampon J; Kariya R; Okada S
Cancer Immunol Immunother; 2022 May; 71(5):1017-1031. PubMed ID: 34545416
[TBL] [Abstract][Full Text] [Related]
11. The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
Moreno L; Perez C; Zabaleta A; Manrique I; Alignani D; Ajona D; Blanco L; Lasa M; Maiso P; Rodriguez I; Garate S; Jelinek T; Segura V; Moreno C; Merino J; Rodriguez-Otero P; Panizo C; Prosper F; San-Miguel JF; Paiva B
Clin Cancer Res; 2019 May; 25(10):3176-3187. PubMed ID: 30692097
[TBL] [Abstract][Full Text] [Related]
12. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
13. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
Zhu C; Song Z; Wang A; Srinivasan S; Yang G; Greco R; Theilhaber J; Shehu E; Wu L; Yang ZY; Passe-Coutrin W; Fournier A; Tai YT; Anderson KC; Wiederschain D; Bahjat K; Adrián FJ; Chiron M
Front Immunol; 2020; 11():1771. PubMed ID: 32922390
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
van de Donk NW; Janmaat ML; Mutis T; Lammerts van Bueren JJ; Ahmadi T; Sasser AK; Lokhorst HM; Parren PW
Immunol Rev; 2016 Mar; 270(1):95-112. PubMed ID: 26864107
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
16. Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity.
Yu T; Qiao C; Lv M; Tang L
BMC Biotechnol; 2019 May; 19(1):28. PubMed ID: 31118070
[TBL] [Abstract][Full Text] [Related]
17. CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma.
Chen X; Wong OK; Reiman L; Sherbenou DW; Post L
Mol Cancer Ther; 2024 Feb; 23(2):127-138. PubMed ID: 37816503
[TBL] [Abstract][Full Text] [Related]
18. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
[No Abstract] [Full Text] [Related]
19. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS
Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]